305 related articles for article (PubMed ID: 27143871)
21. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis.
Hansen NC; Skriver A; Brorsen-Riis L; Balsløv S; Evald T; Maltbaek N; Gunnersen G; Garsdal P; Sander P; Pedersen JZ
Respir Med; 1994 Aug; 88(7):531-5. PubMed ID: 7972979
[TBL] [Abstract][Full Text] [Related]
22. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum.
Ayfer Aytemur Z; Baysak A; Ozdemir O; Köse T; Sayiner A
Wien Klin Wochenschr; 2015 Apr; 127(7-8):256-61. PubMed ID: 25595117
[TBL] [Abstract][Full Text] [Related]
23. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate) versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease.
Mahler DA; Kerwin E; Ayers T; FowlerTaylor A; Maitra S; Thach C; Lloyd M; Patalano F; Banerji D
Am J Respir Crit Care Med; 2015 Nov; 192(9):1068-79. PubMed ID: 26177074
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
[TBL] [Abstract][Full Text] [Related]
25. [Steroid response after long-term treatment with oral N-acetylcysteine in patients with chronic obstructive bronchitis].
Evald T; Hansen M; Balsløv S; Brorson-Riis L; Hansen NC; Maltbaek N; Thorshauge H
Ugeskr Laeger; 1989 Nov; 151(46):2076-8. PubMed ID: 2688231
[TBL] [Abstract][Full Text] [Related]
26. High-dose N-acetylcysteine in the prevention of COPD exacerbations: rationale and design of the PANTHEON Study.
Zheng JP; Wen FQ; Bai CX; Wan HY; Kang J; Chen P; Yao WZ; Ma LJ; Xia QK; Gao Y; Zhong NS;
COPD; 2013 Apr; 10(2):164-71. PubMed ID: 23061828
[TBL] [Abstract][Full Text] [Related]
27. Double-blind study of OM-85 in patients with chronic bronchitis or mild chronic obstructive pulmonary disease.
Solèr M; Mütterlein R; Cozma G;
Respiration; 2007; 74(1):26-32. PubMed ID: 16772707
[TBL] [Abstract][Full Text] [Related]
28. Update on the pathological processes, molecular biology, and clinical utility of N-acetylcysteine in chronic obstructive pulmonary disease.
Tse HN; Tseng CZ
Int J Chron Obstruct Pulmon Dis; 2014; 9():825-36. PubMed ID: 25125976
[TBL] [Abstract][Full Text] [Related]
29. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review.
Stey C; Steurer J; Bachmann S; Medici TC; Tramèr MR
Eur Respir J; 2000 Aug; 16(2):253-62. PubMed ID: 10968500
[TBL] [Abstract][Full Text] [Related]
30. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
31. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine.
Santus P; Corsico A; Solidoro P; Braido F; Di Marco F; Scichilone N
COPD; 2014 Dec; 11(6):705-17. PubMed ID: 24787454
[TBL] [Abstract][Full Text] [Related]
32. Cilomilast for COPD: results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.
Rennard SI; Schachter N; Strek M; Rickard K; Amit O
Chest; 2006 Jan; 129(1):56-66. PubMed ID: 16424413
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
Gotfried MH; Kerwin EM; Lawrence D; Lassen C; Kramer B
COPD; 2012 Dec; 9(6):629-36. PubMed ID: 23020650
[TBL] [Abstract][Full Text] [Related]
34. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
Blasi F; Schaberg T; Centanni S; Del Vecchio A; Rosignoli MT; Dionisio P
Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
Kinoshita M; Lee SH; Hang LW; Ichinose M; Hosoe M; Okino N; Prasad N; Kramer B; Fukuchi Y;
Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
[TBL] [Abstract][Full Text] [Related]
36. New developments in the treatment of COPD: comparing the effects of inhaled corticosteroids and N-acetylcysteine.
van Overveld FJ; Demkow U; Górecka D; de Backer WA; Zielinski J
J Physiol Pharmacol; 2005 Sep; 56 Suppl 4():135-42. PubMed ID: 16204787
[TBL] [Abstract][Full Text] [Related]
37. The efficacy of
Huang C; Kuo S; Lin L; Yang Y
Ther Adv Respir Dis; 2023; 17():17534666231158563. PubMed ID: 36927162
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Siler TM; Kerwin E; Sousa AR; Donald A; Ali R; Church A
Respir Med; 2015 Sep; 109(9):1155-63. PubMed ID: 26117292
[TBL] [Abstract][Full Text] [Related]
39. [Multicenter, double-blind study of oral acetylcysteine vs. placebo].
Brocard H; Charpin J; Germouty J
Eur J Respir Dis Suppl; 1980; 111():65-9. PubMed ID: 7011834
[TBL] [Abstract][Full Text] [Related]
40. Effect of Orally Administered N-Acetylcysteine on Chronic Bronchitis: A Meta-analysis.
Wei J; Pang CS; Han J; Yan H
Adv Ther; 2019 Dec; 36(12):3356-3367. PubMed ID: 31598901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
